Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Flexner

Showing results (91-100 of 137) with videos related to

Pageof 14
Sort By:
Pharmaceutics|December 23, 2023
Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and HumansHannah Kinvig, Rajith K R Rajoli, Henry Pertinez, et al.
Antiviral Therapy|May 28, 2005
Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapyMarta Boffito, Edward Acosta, David Burger, et al.
HIV Clinical Trials|January 24, 2006
Psychological distress and physical pain appear to have no short-term adverse impact on plasma HIV-1 RNA levels in patients on successful HAARTRichard E Nettles, Tara L Keiffer, Joseph Cofrancesco, et al.
Annual Review of Pharmacology and Toxicology|September 16, 2025
The Promises and Prospects of Long-Acting Therapeutics for Treatment and Prevention of Infectious DiseasesAdeniyi Olagunju, Simone Perazzolo, Zachary R Stephen, et al.
HIV Clinical Trials|August 28, 2007
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of responseDaniel Podzamczer, Martin S King, Cheri E Klein, et al.
Antiviral Therapy|July 26, 2005
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugsMarta Boffito, Edward Acosta, David Burger, et al.
Clinical Pharmacology and Therapeutics|May 14, 2022
Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and ComedicationsCatia Marzolini, Daniel R Kuritzkes, Fiona Marra, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 13, 2018
Interest of Youth Living With HIV in Long-Acting AntiretroviralsEthel D Weld, Md Sohel Rana, Ronald H Dallas, et al.
Antiviral Therapy|October 12, 2007
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenzPaul A Pham, Craig W Hendrix, Patricia Barditch-Crovo, et al.
Journal of Clinical Microbiology|June 5, 2009
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virionsNoriaki Hosoya, Zhaohui Su, Timothy Wilkin, et al.
Pageof 14

Showing results (91-100 of 137) with videos related to

Sort By:
Pageof 14
Pharmaceutics|December 23, 2023
Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and HumansHannah Kinvig, Rajith K R Rajoli, Henry Pertinez, et al.
Antiviral Therapy|May 28, 2005
Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapyMarta Boffito, Edward Acosta, David Burger, et al.
HIV Clinical Trials|January 24, 2006
Psychological distress and physical pain appear to have no short-term adverse impact on plasma HIV-1 RNA levels in patients on successful HAARTRichard E Nettles, Tara L Keiffer, Joseph Cofrancesco, et al.
Annual Review of Pharmacology and Toxicology|September 16, 2025
The Promises and Prospects of Long-Acting Therapeutics for Treatment and Prevention of Infectious DiseasesAdeniyi Olagunju, Simone Perazzolo, Zachary R Stephen, et al.
HIV Clinical Trials|August 28, 2007
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of responseDaniel Podzamczer, Martin S King, Cheri E Klein, et al.
Antiviral Therapy|July 26, 2005
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugsMarta Boffito, Edward Acosta, David Burger, et al.
Clinical Pharmacology and Therapeutics|May 14, 2022
Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and ComedicationsCatia Marzolini, Daniel R Kuritzkes, Fiona Marra, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 13, 2018
Interest of Youth Living With HIV in Long-Acting AntiretroviralsEthel D Weld, Md Sohel Rana, Ronald H Dallas, et al.
Antiviral Therapy|October 12, 2007
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenzPaul A Pham, Craig W Hendrix, Patricia Barditch-Crovo, et al.
Journal of Clinical Microbiology|June 5, 2009
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virionsNoriaki Hosoya, Zhaohui Su, Timothy Wilkin, et al.
Pageof 14